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Abstract
Background: Corticosteroid insensitivity is a major barrier of treatment for some chronic inflammatory diseases, such as
severe asthma, but the molecular mechanism of the insensitivity has not been fully elucidated. The object of this study is to
investigate the role of protein phosphate 2A (PP2A), a serine/threonine phosphatase, on corticosteroid sensitivity in severe
asthma.
Methodology/Principal Findings: Corticosteroid sensitivity was determined by the dexamethasone ability to inhibit TNFa-
induced IL-8 or LPS-induced TNFa production. PP2A expression, glucocorticoid receptor (GR) nuclear translocation defined
as the nuclear/cytoplasmic GR ratio and phosphorylation of GR-Ser
226, c-Jun N-terminal kinase 1 (JNK1) and PP2A were
analysed by Western-blotting. Phosphatase activity was measured by fluorescence-based assay. Okadaic acid (OA), a PP2A
inhibitor, reduced corticosteroid sensitivity with reduced GR nuclear translocation and increased GR phosphorylation in
U937 monocytic cells. PP2A knockdown by RNA interference showed similar effects. IL-2/IL-4 treatment to U937 reduced
corticosteroid sensitivity, and PP2A expression/activity. In peripheral blood mononuclear cells (PBMCs) from severe asthma,
the PP2A expression and activity were significantly reduced with concomitant enhancement of PP2AC-Tyr
307
phosphorylation compared with those in healthy volunteers. As the results, GR-Ser
226 and JNK1 phosphorylation were
increased. The expression and activity of PP2A were negatively correlated with phosphorylation levels of GR-Ser
226.
Furthermore, co-immunoprecipitation assay in U937 cells revealed that PP2A associated with GR and JNK1 and IL-2/IL-4
exposure caused dissociation of each molecule. Lastly, PP2A overexpression increased corticosteroid sensitivity in U937
cells.
Conclusions/Significance: PP2A regulates GR nuclear translocation and corticosteroid sensitivity possibly by dephosphor-
ylation of GR-Ser
226 via dephosphorylation of upstream JNK1. This novel mechanism will provide new insight for the
development of new therapy for severe asthma.
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Introduction
Bronchial asthma has been recognized as a chronic inflamma-
tory disease of the airways with increasing trend of its prevalence.
Currently, most patients with asthma are well controlled on
regular use of inhaled corticosteroid (ICS) with or without long-
acting b2-agonists (LABAs) [1]. However, small population
(approximately 5–10%) of asthmatics develops severe asthma,
and has greater morbidity with corticosteroid insensitive and a
disproportionate contribution to health care spending [2].
Therefore, understanding the molecular mechanism of corticoste-
roid insensitivity may provide clues to improve treatment for
patients with severe asthma.
The impairment of corticosteroid responsiveness observed in
severe asthma has been induced by decreased glucocorticoid
receptor (GR) a expression, increased decoy GR receptor (GRb),
defected ligand binding for GR, reduced GR nuclear translocation
and GR/glucocorticoid response elements (GREs) binding [3] as
well as HDAC2 reduction. In some asthmatics with corticosteroid
insensitivity, nuclear translocation of GR in response to dexa-
methasone was impaired [4]. Although highly phosphorylated GR
by mitogen-activated protein kinase (MAPK) might affect GR
nuclear translocation [5], the mechanism for the effect is unclear.
Human GR is known to be phosphorylated at three major sites
on its N terminus (Ser
203, Ser
211 and Ser
226) [6]. Although
phosphorylation of Ser
203 and Ser
211 is required for full GR
activity [7–9], phosphorylation of Ser
226 is inhibitory to GR
function [10–12], suggesting that Ser
226 phosphorylation could be
a biomarker for inactivated GR and involved in reduced nuclear
retention of active GR.
Previous studies indicate that c-Jun N-terminal kinase (JNK) is
responsible for phosphorylation of Ser
226 on GR inactivation.
Phosphorylation of GR at Ser
226 by JNK has been shown to
inhibit GR transcriptional activation [10] and also regulate GR
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GR phosphorylation at Ser
226 was increased in PBMCs from
severe asthma [13]. In addition, some phosphatases such as
protein phosphatase 2A (PP2A) and protein phosphatase 5 (PP5)
have been reported to modify GR phosphorylation [14].
Interestingly, DeFranco et al. [15] demonstrated that PP2A
inhibition by okadaic acid led to inefficient nuclear retention of
agonist-bound GR. Further, PP2A may intensify GR action
through dephosphorylation of JNK and also regulate GR
translocation into nucleus directly [16].
We therefore hypothesized that defect of PP2A impairs steroid
effects via failure of dephosphorylation of GR at Ser
226 and we
demonstrated this first time in PBMCs obtained from severe
asthmatics.
Results
PP2A inhibition induced corticosteroid sensitivity
As shown in Figure 1A, pretreatment of okadaic acid (OA;
10
29 M) increased IC50 values of dexamethasone on TNFa-
induced IL-8 release in U937 monocytic cell line by 2.4 fold,
suggesting OA reduced dexamethasone sensitivity. OA also
significantly inhibited dexamethasone (10
27 M)-induced GR
nuclear translocation defined as the ratio of nuclear and
cytoplasmic GR band density (see Figure 1B). Cell viabilities were
more than 90% in all treatments. In addition, OA treatment
caused enhanced GR phosphorylation at Ser
226 and JNK1, which
is known upstream kinase of GR phosphorylation (see Figure 1C
and D). As OA is not selective PP2A inhibitor, PP2A catalytic
subunit a (PP2ACa) has been knocked down by RNA interference.
Western blotting analysis confirmed 30% knockdown (KD) of
PP2AC in U937 cells and cell viabilities were more than 70% (data
not shown). As shown in Figure 1E, PP2A-KD significantly
decreased inhibitory effects of dexamethasone on TNFa-induced
IL-8 release in U937 cells. Thus, PP2A is a key phosphatase to
control corticosteroid function.
PP2A expression and activity were reduced in IL-2/IL-4
treated corticosteroid insensitive model
It is well known that co-treatment of IL-2 and IL-4 induces
corticosteroid insensitivity in U937 cell. In this experiment, IL-2
(20 ng/ml)/IL-4 (10 ng/ml) treatment for 48 h significantly
increased IC50 values of dexamethasone on TNFa-induced IL-8
release (see Figure 2A). As seen in Figure 2B, PP2A level in total
cell extracts was significantly reduced in IL-2/IL-4 treated cells.
Cell viabilities were more than 90% in all treatments. Further-
more, the activity of PP2A immunoprecipitated from cells treated
with IL-2/IL-4 was also significantly reduced, suggesting that IL-
2/IL-4 reduced both activity and protein expression (see
Figure 2C). Although PP2A activity is reported to be reduced
when it is phosphorylated at Thr
307, IL-2/IL-4 significantly
increased PP2A phosphorylation. At the same time, IL-2/IL-4
treatment significantly enhanced GR phsophorylation at Ser
226
and JNK1 (see Figure 2E and F), but not JNK2/3 (data not
shown).
PP2A expression and activity were reduced in PBMCs
from severe asthma
In PBMCs from patients with severe asthma (SA), protein
expression of PP2A, but not PP1, was significantly reduced
compared with those from healthy volunteers (HV) (see Figure 3A
and B) (PP2A: 1.160.06 in HV, 0.7660.04 in SA). In addition,
immunoprecipitated PP2A activity was significantly reduced in
PBMCs form severe asthmatics as well as PP2A expression (see
Figure 3C). At the same time, phosphorylation levels of GR at
Ser
226 (see Figure 3 D) and JNK1, but not JNK2/3(see Figure S1
A and B), were significantly increased in PBMCs from patients
with severe asthma. As shown in Figure 3E, PP2AC protein
expression corrected to b actin expression was significantly and
negatively correlated with the level of GR-Ser
226 phospho-
rylation. PP2A activity was also correlated with GR-Ser
226
Figure 1. Effects of PP2A inhibitor on glucocorticoid function. Effect of okadaic acid (OA; 10
29 M) on corticosteroid sensitivity (A), GR nuclear
translocation (B), phosphorylation levels of GR-Ser
226 (C) and JNK1 (D) in U937 cells (n=3–4). E: Effect of PP2A siRNA on IC50 of dexamethasone on
TNFa-induced IL-8 (n=7). Values represent means 6 SEM.
# P,0.05,
## P,0.01 (vs. non-treatment control; NT), * P,0.05.
doi:10.1371/journal.pone.0027627.g001
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and expression were also negatively correlated with JNK1
phosphorylation (see Figure S2 B and C). There was also a
positive correlation between JNK1 and GR-Ser
226 phosphoryla-
tion (see Figure S1C). As same with IL-2/IL-4 model, PP2A was
also significantly phosphorylated at Thr
307 in PBMCs of severe
asthma (see Figure 3F).
PP2A dissociates from GR and JNK1 in steroid insensitive
U937 cell model
Whole protein was extracted from non-treated U937 cells, and
PP2A and JNK1 were co-immunoprecipitaed with GR. As shown
in Figure 4A, PP2A and JNK1 were detected in GR immunopre-
cipitates, suggesting that GR, PP2A and JNK1 were in same
complex. In the same way, co-immunoprecipitation with GR or
Figure 2. PP2A function in IL-2/IL-4-treated U937 cells. Effects of IL-2/IL-4 co-treatment for 48 h on IC50 of dexamethasone on TNFa-induced
IL-8 release (A), PP2AC protein expression (B), immunoprecipitated PP2A (IP-P2A) activity (C), PP2AC-Tyr
307 phosphorylation(D), GR-Ser
226
phosphorylation (E) and JNK1 phosphorylation (F). Values represent means 6 SEM (n=3–4).
# P,0.05,
## P,0.01 (vs. non-treatment control; NT).
doi:10.1371/journal.pone.0027627.g002
Figure 3. PP2Ac expression and activity in severe asthma. PP2AC protein expression (A), PP1 protein expression (B), immunoprecipitated
PP2A (IP-PP2A) activity (C), phosophorylation levels of GR-Ser
226 (D) and PP2AC-Tyr
307 (F) in PBMCs from severe asthmatics (SA) and healthy
volunteers (HV). E. Correlation between PP2AC expression and GR-Ser
226 phosphorylation. The dotted lines show 95% confidence interval.
# P,0.05,
## P,0.01 (vs. HV).
doi:10.1371/journal.pone.0027627.g003
Corticosteroid Insensitivity by Defects of PP2A
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e27627JNK1 was conducted at 48 h after IL-2/IL-4 treatment. As shown
in Figure 4B and 4C, IL-2/IL-4 treatment inhibited PP2AC
association with GR, and GR-associated PP2A activity. Further-
more, IL-2/IL-4 treatment also inhibited association of JNK1 and
PP2AC (see Figure 4C), and JNK1 associated PP2A activity (see
Figure 4E).
PP2A overexpression increased GR nuclear translocation
and increased dexamethasone sensitivity
PP2A overexpression plasmid was transfected and the cells were
used 20 h after transfection. Empty vector was also transfected as
control. Although dexamethasone at 10
29 M significantly in-
creased GR nuclear translocation, PP2A overexpression signifi-
cantly increased GR nuclear translocation in U937 cells (see
Figure 5A). The inhibitory response curve of dexamethasone on
LPS-induced IL-8 release was shifted leftward by PP2A overex-
pression (see Figure 5B), and therefore the IC50 value of
dexamethasone on IL-8 release was reduced by PP2A overex-
pression compared with empty vector transfection, suggesting
PP2A overexpression increased corticosteroid sensitivity (IC50 of
dexamethasone: 2.1 nM in PP2A overexpression vs. 6.4 nM in
empty plasmid transfected control) (see Figure 5C).
Discussion
It is previously demonstrated that PBMCs (mainly monocytes)
obtained from patients with severe asthma was corticosteroid
insensitive [4,13]. The impairment of corticosteroid responsiveness
has been reported to be induced by several mechanisms [3].
Although an increase in decoy receptor, GRb, has been identified
as one of important causes of corticosteroid insensitivity, the GRb
isoform was rarely found in monocyte or U937 cells unlikely in
neutrophils and lymphocytes. As another possibility, phosphory-
lation of Ser
226 on GRa is reported to be one of major inhibitory
mechanisms of corticosteroid function [10–12]. In this manuscript,
we demonstrated that the level of GR-Ser
226 phosphorylation was
significantly increased in PBMCs in severe asthma compared with
those in healthy volunteers in agreement with our previous
findings [13]. JNK1 is known to phosphorylate GR-Ser
226 [10,11]
and phosphorylation level of JNK was increased in PBMC from
patients with corticosteroid-resistant asthma [17]. In our samples,
JNK1 phosphorylation was also upregulated in PBMCs in severe
asthma (Fig. S1A) and there was a good correlation between GR-
Ser
226 phosphorylation and JNK1 phosphorylation (Fig. S1C).
Generally the increased phosphorylation level was considered due
to highly activated relevant upstream kinase or impaired
phosphatase activity. As IL-2/IL-4 co-treatment, a well-known
steroid insensitive model [18,19], showed GR-Ser
226 phosphory-
lation and JNK1 activation as well as steroid insensitivity, we used
IL-2/IL-4 model for mechanism assay.
Okadaic acid is a PP2A and PP1 inhibitor at around 1 mM, but
OA selectively inhibits PP2A at lower concentration (around
1 nM) [20,21]. PP2A is a serine/threonine phosphatase, which
regulates cell signal transduction and many cellular functions [22].
In U937 cells, this low concentration (1 nM) of OA clearly
reduced GR nuclear translocation and corticosteroid sensitivity
(Fig. 1A and B). PP2A KD by RNA interference also reduced
dexamethasone sensitivity (Fig. 1E), but PP1 RNAi did not induce
corticosteroid insensitivity (data not shown). Furthermore, there
was no significant reduction of PP1 protein expression in PBMCs
from severe asthma but PP2AC expression was significantly
reduced in severe asthma (Fig. 3A and B). Taken together,
PP2A, but not PP1, is likely a key molecule for corticosteroid
function.
PP2A has been reported to be involved in GR phosphorylation
and GR nuclear translocation [15,16]. Although it has not been
elucidated which site of GR is dephosphorylated by PP2A on
regulation of GR nuclear translocation, we demonstrated here that
PP2A regulates corticosteroid sensitivity through GR-Ser
226
phosphorylation and dephosphorylation in U937 cells. Further-
more, we reported first time that PP2A was down-regulated in
PBMCs from severe asthmatics with a concomitant increase in
GR-Ser
226 phosphorylation (Fig. 3A, C and D). PP2A protein
expression was reduced in PBMCs from severe asthma and IL-2/
IL-4 treated U937 cells, and also very interestingly, immunopre-
cipitated PP2A activity corrected by protein expression was also
decreased in both samples. This suggests that the activity itself was
decreased as well as total protein level.
Figure 4. Association between PP2A and GR/JNK1 in U937 cells. (A) PP2AC and JNK1 expression in GR-immunoprecipitates. Expression levels
of PP2AC in GR (B)- or JNK1 (D)-immunoprecipitates. PP2A activity in GR (C)- and JNK1 (E) immunoprecipitates were also determined. Values represent
means of four experiments 6 SEM.
# P,0.05,
## P,0.01 (vs. non-treatment control; NT).
doi:10.1371/journal.pone.0027627.g004
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regulation of PP2A complexes and activity [23]. PP2AC can be
phosphorylated at Tyr
307 via epidermal growth factor receptor,
insulin receptor and tyrosine kinases such as p60
V-Src and p56
Lck
[24], and phosphorylation of PP2AC leads to reduction of its
activity [25]. We found that phosphorylation levels of PP2AC-
Tyr
307 were significantly increased in PBMCs from severe asthma
and IL-2/IL-4 treated U937 cells (Fig. 2D and 3F). These findings
suggest that hyperphosphorylated PP2AC-Tyr
307 might be one of
mechanisms of PP2A inactivation under steroid resistant condition
including severe asthma. The mechanism of the reduction of PP2A
protein level was not clear.
As well as PP2A KD study, we also conducted PP2A
overexpression by plasmid transfection. Transfection increased
PP2A protein level by approximately 1.5 fold in U937 cells (data
not shown). PP2A overexpression clearly increased GR nuclear
translocation and dexamethasone sensitivity on LPS-induced IL-8
release (Fig. 5). This is another confirmation that PP2A is involved
in GR function and also important evidence that PP2A activator
can be a novel therapeutic approach for severe asthma.
Protein phosphatase 5 (PP5), one of serine/threonine phospha-
tases, which associates with GR-heat shock protein 90 complex
[26,27] has also been reported to influence GR actions [28] and
dephosphorylate GR-Ser
226 [14]. Thus involvement of another
phosphatase cannot be ruled out.
Thus, we demonstrated that PP2A reduced in PBMCs from
patients with severe asthma, and impaired PP2A failed to
dephosphorylate GR-Ser
226 and JNK1. This is one of the
molecular mechanisms of corticosteroid insensitivity in severe
asthma and possibly for other corticosteroid refractory diseases,
and will be a novel therapeutic target for the treatment.
Materials and Methods
Reagents
3-(4,5-dimethylthiazol-2yr)-2-5-diphenyltetrazolium bromide
(MTT), dimethyl sulfoxide (DMSO), phorbol 12-myristate 13-
acetate (PMA) and lipopolysaccharide (LPS) were purchased from
Sigma-Aldrich (Poole, UK). Recombinant Human IL-2 and IL-4
were purchased from R&D Systems Europe (Abingdon, UK). As a
pharmacological inhibitor, okadaic acid (Calbiochem, Darmstadt,
Germany) was used as needed. The rabbit monoclonal antibody to
PP2A catalytic subunit (PP2AC), the rabbit polyclonal anti-GR
(phospho S
226) antibody, and the mouse monoclonal antibody to
b-actin and TATA binding protein TBP were obtained from
Abcam (Cambridge, UK). The rabbit polyclonal anti-GR
antibody, the mouse monoclonal antibody to PP1, PP2AC
(phospho Try
307) and a-tubulin were obtained from Santa Cruz
Biotechnology (Heidelberg, Germany). The rabbit polyclonal anti-
phospho-SAPK/JNK and anti-SAPK/JNK antibodies were
obtained from Cell Signaling Technology (Danvers, MA). As
immunoprecipitation reagents, TrueBlotH anti-rabbit and goat Ig
IP beads were purchased from eBioscience (Hatfield, UK).
Subjects
Peripheral blood mononuclear cells (PBMCs) were obtained
from 7 patients with severe asthma and 10 age-matched healthy
volunteers, and separated by AccuSPIN (Sigma–Aldrich). The
characteristics of subjects were shown in Table 1. This study was
approved by the local ethics committee of Royal Brompton and
Harefield NHS Trust and written informed consent was obtained
from each patient or volunteer.
Cells
The human monocytic cell line U937 [29] (CRL-1593.2
TM) was
obtained from the American Type Culture Collection (ATCC,
Rockville, MD). Cells were cultured in complete growth medium
(PRMI 1640; Sigma–Aldrich) supplemented with 10% fetal bovine
Figure 5. Effect of PP2A overexpression on glucocorticoid function in U937 cells. (A) Fold changes of GR nuclear translocation defined as
the ratio of nuclear and cytoplasmic GR (N/C) over no Dex control (NT). Dexamethasone inhibitory response curve (B) and IC50 values of Dex (C) on
LPS-induced TNFa production. Values represent means 6 SEM (n=3): ** P,0.01 between groups.
doi:10.1371/journal.pone.0027627.g005
Table 1. Characteristics of subjects.
Healthy volunteers
(n=10)
Severe asthmatics
(n=7)
Gender (M:F) 2:8 3:4
Age 50.262.6 45.765.3
Atopic 2/10 5/7
FEV1.0 %pred. 92.062.4 76.065.6*
FEV1.0/FVC 78.261.5 69.063.3*
ICS none 7/7
629692 mg
FP equivalent dose
Oral prednisolone none 6/7
17.561.7 mg
Albuterol none 7/7
*p,0.05 (vs. healthy volunteers).
ICS: inhaled corticosteroid, FP: fluticasone propionate.
doi:10.1371/journal.pone.0027627.t001
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atmosphere with 5% CO2. Cell viability was assessed microscop-
ically by trypan blue staining. Cell toxicity was determined by
MTT assay as needed. Cells were exposed to IL-2 (20 ng/ml) and
IL-4 (10 ng/ml) for 48 h to induce corticosteroid insensitivity.
Cell Lysis, Immunoprecipiation, and Western Blotting
Cell protein extracts were prepared using modified RIPA buffer
(50 mM Tris HCL pH 7.4, 0.5–1.0% NP-40, 0.25% Na-
deoxycholate, 150 mM NaCl with freshly added complete
protease (Roche, Mannheim, Germany)), as described previously
[30,31]. Phosphatase inhibitor (Active Motif, Rixensart, Belgium)
was used as needed. Nuclear extraction was performed using
Active Motif kit. Protein concentration was determined using the
Bio-Rad Protein Assay (Bio-Rad). Immunoprecipitation was
conducted with anti-PP2A antibody (Bethyl, Montgomery, TX)
for phosphatase activity assay or anti-GR Ab or anti-JNK1
antibody (Santa Cruz Biotechnology) for co-immunoprecipitation
assay. Protein extracts (40 mg protein per well, and 60 mg protein
for phosphoprotein detection) or immunoprecipitates were
analyzed by SDS-PAGE (Invitrogen, Paisley, UK) and detected
with Western blot analysis by chemiluminescence (ECL Plus; GE
Healthcare, Chalfont St. Giles, UK). Protein expression levels of
PP2AC and PP1 were expressed relative to b-actin expression used
as a control for protein loading. Phosphorylation levels of GR-
Ser
226, JNK1 and PP2AC-Tyr
307 were expressed relative to total
GR, JNK1 and PP2AC, respectively. In co-immunoprecipitation
study, expression PP2AC in GR- or JNK1-immunoprecipitates
was expressed relative to GR or JNK1 expression in each
immunoprecipitates, respectively.
Glucocorticoid receptor nuclear translocation
Cells were treated with Dex (10
27 M) for 1 h. Nuclear and
cytoplasmic GR were measured by Western blot. TBP (for nuclear
protein) or a tubulin (for cytoplasmic protein) expression was used
as a control for protein loading. As an index of GR nuclear
translocation, the ratio of nuclear GR to cytoplasmic GR was
calculated.
Corticosteroid sensitivity
Cells were treated with dexamethasone (Dex) for 45 min,
followed by TNFa-stimulation (10 ng/ml overnight) or LPS
(100 ng/ml for 4 h). TNFa-induced IL-8 or LPS-induced TNFa
concentrations were determined by sandwich ELISA according to
the manufacturer’s instructions (R&D Systems Europe). IC50
values for dexamethasone on IL-8 or TNFa production were
calculated using the computer program Prism 4.0 (GraphPad
Software Inc., San Diego, CA) as a marker for steroid sensitivity
(Dex-IC50).
Protein phosphatase activity
Phosphatase activity was assayed by using the SensoLyteTM
MFP Protein Phosphatase Assay system (AnaSpec, San Jose, CA).
Cell lysates were immunoprecipitated with anti-PP2A antibody.
Immunoprecipitated PP2A with assay buffer (40 mM Tris HCl
pH 8.4, 34 mM MgCl2, 4 mM EDTA, 4 mM DTT) was
transferred to a 96-well plate, and then the same volume of 3-
O-methylfluorescein phosphate (MFP) reaction solution in 1 M
DTT in assay buffer) was added. PP2A-induced dephosphoryla-
tion was monitored by measuring the fluorescence of MFP
product. Phosphatase activity was calculated as the slope of
fluorescence recordings and expressed as arbitrary fluorescence
units per microgram of protein.
RNA interference
PP2A catalytic subunit a siRNAs (Hs_PPP2CA_6, 5, 7 and 3)
and non-silencing scrambled control siRNA (AllStars Negative
Control siRNA) were purchased from QIAGEN (Crawley, UK).
The siRNA sequences were transfected using an HVJ Envelope
(HVJ-E) Vector Kit GenomONE-Neo (Ishikawa Sangyo Kaisha
Ltd., Osaka, Japan) by modified methods described in the
manufacturer’s instructions and by Tsuchiya et al. [32]. Briefly,
HVJ-E (0.5 AU) was mixed with 20 ml of siRNA solution (0.5 mM)
and 4 ml of Reagent B. After centrifugation, the pellet was
resuspended in 25 ml of buffer, followed by the addition of 10 mlo f
Reagent C. The siRNA-HVJ-E mixture was combined with
1610
6 cells and centrifuged at 12,000 rpm for 20 min at 4uC. The
cells were resuspended in 2 ml of culture media and incubated for
72 h.
Transfection
Transfections were done by NucleofectionH (Lonza, Basel,
Switzerland), according to the manufacturer’s instructions. 2 mgo f
DNA/plasmids (pCMV6 Entry, OriGene Technologies, Rock-
ville, MD) containing the human PP2A catalytic subunit, alpha
isoform (PP2ACa) gene were transfected to U937 cells pretreated
with 50 ng/ml of PMA for 4 h. 20 h after the transfection, the
medium was changed to the appropriate treatment in 1% FBS
medium.
Statistical analysis
Comparisons of two groups of data were performed using
Mann-Whitney U test or paired t test. Correlation coefficients
were calculated with the use of Pearson method or Spearman’s
rank method. Other data were analyzed by ANOVA with post hoc
test adjusted for multiple comparisons (Bonferroni’s test), as
appropriate. The difference was considered statistically significant
if P,.05. Descriptive statistics were expressed as the mean 6
SEM.
Supporting Information
Figure S1 JNK phosphorylation levels in PBMCs from
severe asthmatics. Phosphorylation levels of JNK1 (A) and
JNK2/3 (B). C, Correlation between JNK1 phosphorylation and
GR-Ser
226 phosphorylation levels (seven healthy volunteers; HV
and seven severe asthmatics; SA). The dotted lines show 95%
confidence interval. Individual values and means of seven subjects
are shown:
## P,0.01 (vs. HV).
(TIF)
Figure S2 Correlation between PP2A and GR-Ser
226/
JNK1 phosphorylation. A and B, Correlation between
immunoprecipitate PP2A (IP-PP2A) activity and GR-Ser
226
(A)/JNK1 (C) phosphorylation levels (four healthy volunteers;
HV and seven severe asthmatics; SA). C, Correlation between
PP2AC protein expression and JNK1 phosphorylation levels
(seven HV and seven SA). The dotted lines show 95% confidence
interval.
(TIF)
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